Background
==========

Vaccination against liver stage malaria antigens can induce T cell-mediated immunity to the disease \[[@B1]\]. A viral vector vaccination regime undergoing Phase 2b clinical testing uses chimpanzee adenovirus 63 (ChAd63) and Modified Vaccinia virus Ankara (MVA) encoding liver stage antigen Thrombospondin-Related Adhesion Protein (TRAP) fused to a malaria multi-epitope string (ME). This regime induces high frequencies of antigen-specific T cells, providing 21% sterile protection and a delay to patent parasitaemia in a further 36% of vaccinees, following controlled human *Plasmodium falciparum* malaria infection (CHMI). Monofunctional IFNg-producing CD8^+^ T cells correlate with vaccine-induced protection but the associated protective mechanisms remain unidentified \[[@B2]\]. Developing standardized immunological and functional assays is a research-specific aim of the WHO's Malaria Vaccine Technology Roadmap, with emphasis on novel immunoassays for investigation of cellular products reflecting cell-mediated malaria immunity \[[@B3]\]. Development of an *in vitro* parasite killing assay is underway, which quantifies cell-mediated killing of Plasmodium-infected human hepatocytes and investigates the underlying functional mechanisms. Additionally, the assay aims to compliment *in vivo* CHMI studies.

Materials and methods
=====================

Human hepatoma cell lines were infected with transgenic *P. berghei* sporozoites expressing TRAP from *P. falciparum*. Freshly separated peripheral blood mononuclear cells from partial-HLA class I matched ChAd63.MVA ME-TRAP human vaccinees were enriched for CD8^+^ T cell populations. Following hepatocyte infection, enriched CD8^+^ T cells were added and incubated overnight. Level of infectivity was measured by flow cytometry through expression of GFP under a *P. berghei* promotor. TRAP-specific killing was calculated by subtraction of non-specific killing in wild type *P. berghei*-infected hepatocytes.

Results
=======

Transgenic *P. berghei* sporozoites with full replacement of wild type TRAP infect human hepatoma cells at \>1% frequency. Preliminary results measure a 9.5-22% TRAP-specific reduction of infected hepatocytes after addition of CD8^+^ T cells from ChAd63.MVA ME-TRAP vaccinees. Equivalently, TRAP-specific parasite killing was not detected following addition of CD8^+^ T cells from control volunteers. Conclusions Successful use of transgenic parasites and the preliminary results obtained provide proof of assay concept for this *in vitro* system. Further optimization will permit the investigation of cell-mediated parasite killing of CD8^+^ T cells from a larger number of vaccinees and extend to exploration of vaccine-induced mechanisms of protection.
